How to access Tecvayli from the UAE, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Emirati patient with heavily pre-treated relapsed or refractory multiple myeloma, typically with four or more prior lines including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, may be evaluated by their treating haematologist for Tecvayli (teclistamab). Tecvayli is FDA-approved, developed by Janssen (Johnson & Johnson), and is the first BCMA-directed bispecific T-cell engager approved for multiple myeloma. In the UAE, Tecvayli is not yet broadly registered for routine hospital pharmacy dispensing, which is why your haematologist may be navigating a named-patient import pathway with you.
This guide explains the legal pathway, what your physician needs to provide, typical timelines, and where Reserve Meds fits in.
Ask about Tecvayli in UAE
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Tecvayli is a humanised IgG4 bispecific antibody that engages BCMA on malignant plasma cells and CD3 on T cells, redirecting T-cell cytotoxicity to the myeloma clone. Administration is subcutaneous on a step-up dosing schedule (0.06 mg/kg, then 0.3 mg/kg, then 1.5 mg/kg) followed by weekly maintenance at 1.5 mg/kg; after sustained response, less-frequent dosing may be considered. The step-up phase requires hospitalisation for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) monitoring at a facility capable of tocilizumab administration and intensive support. Eligibility centres on prior-line history, performance status, baseline cytopenias, and infection-risk profile. Your haematologist will identify the administering tertiary centre.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Tecvayli legally importable into the UAE?
Yes, via UAE Ministry of Health and Prevention (MoHAP) named-patient import framework, operating with Ministry of Health tertiary-centre coordination. The named-patient mechanism permits a MoHAP-licensed physician at a qualified haematology centre to import a medicine not locally registered when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent alternative is routinely available at that centre, (c) the physician accepts clinical responsibility, and (d) chain of custody through a licensed importer is documented.
For Tecvayli specifically, the application emphasises the centre's capability to manage CRS/ICANS inpatient monitoring during step-up dosing.
How the pathway works, step by step
- Consultation with your treating haematologist. Prior-line documentation, performance-status assessment, cytopenia and infection baseline.
- Administering-centre identification. A qualified the UAE tertiary haematology centre with CRS/ICANS monitoring capability is nominated; beds are booked for the step-up phase.
- MoHAP named-patient application. Your physician files the dossier including clinical rationale, patient reference, centre capability attestation, and dosing plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure Tecvayli from the manufacturer's authorised distribution chain under DSCSA.
- Cold-chain shipment. Tecvayli ships with validated temperature control to the administering hospital pharmacy.
- Step-up admission and ongoing therapy. The tertiary centre admits for step-up dosing, manages CRS/ICANS prophylaxis and treatment, transitions to weekly outpatient maintenance once cleared.
What documentation your physician needs
- Clinical rationale letter confirming diagnosis, prior-line sequence (≥ 4 prior lines with PI / IMiD / anti-CD38 exposure), and Tecvayli as the indicated therapy
- Verification of SCFHS medical licence
- Identification of the administering tertiary centre with CRS/ICANS monitoring attestation
- Patient identifier (anonymised reference where possible)
- Step-up and maintenance dosing plan with supportive-care protocol
Reserve Meds provides a documentation kit that bundles the MoHAP templates reviewers expect to see for BCMA-directed bispecific named-patient files.
Costs and timing
Medicine price: quote on request. You get a written quote for your case before you commit. Inpatient step-up hospitalisation at the administering centre is a separate local cost handled by that hospital. International logistics, MoHAP documentation handling, cold-chain shipment, and coordination add incremental cost. Reserve Meds issues a transparent quote at the start of intake.
We give you a written timeline estimate for your case before you commit.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
A culturally-aware note: the UAE myeloma patients often travel from regional centres to Riyadh or Jeddah tertiary haematology units for step-up hospitalisation. Our coordination includes family-caregiver support during the inpatient phase and prayer-time-sensitive dosing scheduling where feasible.
Reserve Meds's role
- Sourcing. Through our US-licensed pharmaceutical wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and MoHAP review, keyed to the BCMA-bispecific rationale.
- Logistics. Validated cold-chain shipment to the nominated tertiary centre.
- Dedicated case lead. A named point of contact for your family and your haematology team through step-up and maintenance cadence.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating haematologist and the administering centre.
Frequently asked
How does Tecvayli compare with Carvykti CAR-T? Both target BCMA. Tecvayli is an off-the-shelf bispecific given on a subcutaneous schedule; Carvykti is an autologous one-time CAR-T infusion. Your haematologist will select based on disease pace, prior-line pattern, and centre capability.
Where will the step-up admission happen? At an Emirati tertiary haematology centre with CRS/ICANS experience, your physician nominates the site and coordinates beds.
What is the infection risk? Bispecifics targeting BCMA are associated with hypogammaglobulinaemia and opportunistic infection risk, particularly CMV and respiratory viruses; IVIG supplementation and antimicrobial prophylaxis are standard. Your team will manage.
Will insurance cover this? Cash-pay is the default for named-patient imports. Some UAE private insurers and MoH pathways consider case-by-case reimbursement; we supply documentation but do not process claims directly.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-23.
Abu Dhabi and Dubai
This guide covers the whole UAE, including Abu Dhabi and Dubai. At federal level, medicines are regulated by the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP). MOHAP also issues permits to import medicines for personal use. Hospitals, clinics and doctors are licensed by the health authority of their own emirate: the Department of Health Abu Dhabi (DoH) in Abu Dhabi, and the Dubai Health Authority (DHA) in Dubai.
In practice, the hospital that treats you follows the rules of its own emirate, so the paperwork is prepared for that hospital. Tell us which hospital or doctor is treating you, in Abu Dhabi, Dubai or another emirate, and we prepare the document pack for that route.
Sources: Department of Health Abu Dhabi; Dubai Health Authority, Health Regulation Sector; MOHAP, permit to import medicines for personal use; Simmons & Simmons, UAE pharmaceutical law and the Emirates Drug Establishment.
Frequently asked questions
How can I get Tecvayli in the UAE if it is not approved or available there?
Reserve Meds coordinates US-sourced Tecvayli for patients in the UAE through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for the UAE and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Tecvayli in the UAE through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Tecvayli. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in the UAE, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Tecvayli in the UAE through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Tecvayli to a patient in the UAE?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Tecvayli to your treating physician or hospital pharmacy in the UAE, with appropriate handling for the product.
How long does it take, and what does Tecvayli in the UAE cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Tecvayli in the UAE?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.